Cargando…

Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial

BACKGROUND: COVID-19 morbidity and mortality remains high and the need for safe and effective drugs continues despite vaccines. METHODS: Double-blind, placebo-controlled, multi-centre, randomised, parallel group phase 2 trial to evaluate safety and efficacy of oral angiotensin II type 2 receptor ago...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tornling, Göran, Batta, Rohit, Porter, Joanna C., Williams, Bryan, Bengtsson, Thomas, Parmar, Kartikeya, Kashiva, Reema, Hallberg, Anders, Cohrt, Anne Katrine, Westergaard, Kate, Dalsgaard, Carl-Johan, Raud, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542174/ https://www.ncbi.nlm.nih.gov/pubmed/34723163 http://dx.doi.org/10.1016/j.eclinm.2021.101152

Ejemplares similares

Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats
por: Tornling, Göran, et al.
Publicado: (2023)

A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
por: Herrick, Ariane L, et al.
Publicado: (2022)

Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists
por: Vasile, Silvana, et al.
Publicado: (2020)

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
por: Kuna, Piotr, et al.
Publicado: (2016)

Cell Recovery in Bronchoalveolar Lavage Fluid in Smokers Is Dependent on Cumulative Smoking History
por: Karimi, Reza, et al.
Publicado: (2012)

Direct Angiotensin AT2 Receptor Stimulation Using a Novel AT2 Receptor Agonist, Compound 21, Evokes Neuroprotection in Conscious Hypertensive Rats
por: McCarthy, Claudia A., et al.
Publicado: (2014)

Bronchoalveolar Lavage Results Are Independent of Season, Age, Gender and Collection Site
por: Olsen, Helga H., et al.
Publicado: (2012)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study
por: Hallberg, Inger, et al.
Publicado: (2009)

Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer’s Disease?
por: Gallo-Payet, Nicole, et al.
Publicado: (2011)

N-Aryl Isoleucine Derivatives as Angiotensin II AT(2) Receptor Ligands
por: Behrends, Malte, et al.
Publicado: (2014)

Facilitation of TRKB Activation by the Angiotensin II Receptor Type-2 (AT2R) Agonist C21
por: Laukkanen, Liina, et al.
Publicado: (2021)

Intranasal Administration of the Antisecretory Peptide AF-16 Reduces Edema and Improves Cognitive Function Following Diffuse Traumatic Brain Injury in the Rat
por: Clausen, Fredrik, et al.
Publicado: (2017)

Pathological Insight into 5-HT(2B) Receptor Activation in Fibrosing Interstitial Lung Diseases
por: Löfdahl, Anna, et al.
Publicado: (2020)

Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo
por: Lee, Seyoung, et al.
Publicado: (2012)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase
por: Hallberg, Mathias, et al.
Publicado: (2020)

Synergism between Angiotensin receptors ligands: Role of Angiotensin‐(1‐7) in modulating AT(2)R agonist response on nitric oxide in kidney cells
por: Patel, Sanket, et al.
Publicado: (2020)

Calibration and assessment of channel-specific biases in microarray data with extended dynamical range
por: Bengtsson, Henrik, et al.
Publicado: (2004)

Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19
por: Issa, Hawraa, et al.
Publicado: (2021)

Bridging the gender gap: seven principles for achieving gender balance
por: Roseberry, Lynn, et al.
Publicado: (2016)

The angiotensin II receptor type 2 agonist CGP 42112A stimulates NO production in the porcine jejunal mucosa
por: Ewert, Sara, et al.
Publicado: (2003)

Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor
por: Ito, Yusuke, et al.
Publicado: (2018)

CGP42112: the full AT(2) receptor agonist and its role in the renin–angiotensin–aldosterone system: no longer misunderstood
por: Restrepo, Yazmin M., et al.
Publicado: (2022)

β-Arrestin–Biased Angiotensin II Receptor Agonists for COVID-19
por: Manglik, Aashish, et al.
Publicado: (2020)

Structural and Energetic Effects of A(2A) Adenosine Receptor Mutations on Agonist and Antagonist Binding
por: Keränen, Henrik, et al.
Publicado: (2014)

Association of seven renin angiotensin system gene polymorphisms with restenosis in patients following coronary stenting
por: Zhu, Min, et al.
Publicado: (2017)

Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD
por: Löfdahl, Magnus, et al.
Publicado: (2011)

Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19
por: Vofo, Gaelle, et al.
Publicado: (2020)

A Pepducin Derived from the Third Intracellular Loop of FPR2 Is a Partial Agonist for Direct Activation of This Receptor in Neutrophils But a Full Agonist for Cross-Talk Triggered Reactivation of FPR2
por: Gabl, Michael, et al.
Publicado: (2014)

More Treatment, but Not Less Anxiety and Mood Disorders: Why? Seven Hypotheses and Their Evaluation
por: Ormel, Johan, et al.
Publicado: (2023)

Non-linear transverse dynamics for storage rings with applications to the low-energy antiproton ring (LEAR) at CERN
por: Bengtsson, Johan
Publicado: (1988)

Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury
por: Menk, Mario, et al.
Publicado: (2018)

Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
por: Shen, Liang, et al.
Publicado: (2022)

Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study
por: Ekström, Magnus, et al.
Publicado: (2014)

Cancer incidence in Stockholm firefighters 1958–2012: an updated cohort study
por: Kullberg, Cecilia, et al.
Publicado: (2017)

Larval outbreaks in West Greenland: Instant and subsequent effects on tundra ecosystem productivity and CO(2) exchange
por: Lund, Magnus, et al.
Publicado: (2017)

The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia
por: Irani, Roxanna A., et al.
Publicado: (2009)

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
por: Han, Jee-Young, et al.
Publicado: (2010)

From Agonist to Antagonist: Modulation of the Physiological Action of Angiotensins by Protein Conjugation—Hemodynamics and Behavior
por: Zamolodchikova, Tatyana S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_024jvr79s2iktjp7ei6qaekqrs